Biofabri retains Stifel to incorporate partner for EUR 200m
Biofabri encarga a Stifel la entrada de un socio por EUR 200m
Intel ID : 393150
|
||||
Bidder
|
Target
|
| Intel ID | 393150 | |
| Value | EUR 200,00m | |
| Native Currency | Euro (EUR) | |
|
Financial Data - Biofabri
(31 Dec 2022) |
Revenue: - EBITDA: - Net Debt: - People: 7 |
|
| Date |
 |
|
| Country |  |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Primary Subsector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution (Primary) 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.05.09 Neurology (Primary) 30 Healthcare / 30.05 Specialized Medicine |
|
| Secondary Subsectors (TTRSC) |
30.01.04 Specialty Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.05.09 Neurology 30 Healthcare / 30.05 Specialized Medicine |
||
| Secondary Sectors (TTRSC) |
30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Secondary Sectors (TTRSC) |
30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Country |
|
||
| Website |
|
||
| Description |
|
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Secondary Sectors (TTRSC) |
30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.01.04 Specialty Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Financial Advisory
| Parties | Advisor | Notes from Advisors | |||||
|---|---|---|---|---|---|---|---|
|
|
- |
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.